Haleon plc (HLN)vsPrestige Brand Holdings Inc (PBH)
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
PBH
Prestige Brand Holdings Inc
$61.13
-1.40%
HEALTHCARE · Cap: $2.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 899% more annual revenue ($11.03B vs $1.10B). PBH leads profitability with a 16.9% profit margin vs 15.1%. PBH appears more attractively valued with a PEG of 1.97. HLN earns a higher WallStSmart Score of 58/100 (C).
HLN
Buy58
out of 100
Grade: C
PBH
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Margin of Safety
-156.0%
Fair Value
$25.77
Current Price
$61.13
$35.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 29.1%
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
Expensive relative to growth rate
Revenue declined 2.4%
Earnings declined 20.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : PBH
The strongest argument for PBH centers on P/E Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 29.1%.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : PBH
The primary concerns for PBH are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
HLN profiles as a value stock while PBH is a declining play — different risk/reward profiles.
PBH carries more volatility with a beta of 0.40 — expect wider price swings.
HLN is growing revenue faster at 0.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 57/100), backed by strong 15.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Prestige Brand Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company is headquartered in Tarrytown, New York.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?